Comparison · NCT02685709-dd0652f8
RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients of Those Completing the RCT Phase Who Entered the Study Extension Phase
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients of Those Completing the RCT Phase Who Entered the Study Extension Phase. Trial comparisons, record NCT02685709-dd0652f8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02685709-dd0652f8
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.63 | 0.496 | 0.746 | wilson | |
| Risk in group 2 | 0.514 | 0.356 | 0.67 | wilson | |
| Risk difference, group 1 minus group 2 | 0.115 | -0.0897 | 0.312 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.22 | 0.836 | 1.79 | log | |
| Odds ratio, group 1 over group 2 | 1.61 | 0.678 | 3.8 | log | |
| Number needed to treat, for one more participant with the outcome on RCT Phase - Oral than on RCT Phase - Injectables | 8.67 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | RCT Phase - Oral | Oral octreotide capsules~Octreotide capsules: Octreotide capsules 40mg/day, 60mg/day, 80mg/day | 34 | 54 | OG000 |
| Group 2 | RCT Phase - Injectables | Injectable somatostatin analogs (octreotide or lanreotide)~Injectable Somatostatin Analogs (octreotide or lanreotide): Octreotide - 10, 20, 30mg. Lanreotide 60,90, 120mg. | 18 | 35 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Proportion of Patients of Those Completing the RCT Phase Who Entered the Study Extension Phase
- Description
Proportion of patients of those completing the RCT phase (at a time octreotide capsules were not commercially available at the specific country), who entered the Study Extension phase, overall and by treatment group
- Time frame
- 62 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
- NCT number
- NCT02685709
- Phases
- PHASE3
- Conditions
- Acromegaly
- Interventions
- Octreotide capsules
- Lead sponsor
- Chiasma, Inc.
- Results first posted
- 2022-04-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02685709?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02685709-dd0652f8